ArriVent BioPharma (AVBP) Common Equity (2023 - 2026)

ArriVent BioPharma has disclosed Common Equity across 4 years of filings, most recently posting $324.0 million for Q1 2026.

• Common Equity for Q1 2026 came in at $324.0 million, up 59.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $324.0 million (up 59.96% YoY), and the FY2025 annual result was $307.2 million, up 19.24% from the prior year.
• Common Equity came in at $324.0 million for Q1 2026 at ArriVent BioPharma, up from $307.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $324.0 million in Q1 2026 to a low of -$153.2 million in Q4 2023.
• The 4-year median for Common Equity is $257.7 million (2024), against an average of $156.7 million.
• Across the five-year window, Common Equity soared 427.25% in 2024 and slumped 36.25% in 2025, its largest moves.
• ArriVent BioPharma's Common Equity stood at -$153.2 million in 2023, then jumped by 268.19% to $257.7 million in 2024, then gained by 19.24% to $307.2 million in 2025, then gained by 5.45% to $324.0 million in 2026.
• The last three Common Equity figures came in at $324.0 million (Q1 2026), $307.2 million (Q4 2025), and $305.0 million (Q3 2025), per Business Quant data.